Adalimumab

Tofacitinib Compared With Adalimumab in RA Study

Tofacitinib Compared With Adalimumab in RA Study

By

Pfizer has announced top-line results from its Phase 3B/4 study comparing treatment with Xeljanz to adalimumab in patients with moderate to severe rheumatoid arthritis.

Patient-Reported Outcomes Correlate With DAS28 Scores in RA

Patient-Reported Outcomes Correlate With DAS28 Scores in RA

By

"Improved pain management should be explored in patients who report high disease activity."

Lowering Methotrexate Dosage Not Supported in RA Patients Initiating Adalimumab Therapy

Lowering Methotrexate Dosage Not Supported in RA Patients Initiating Adalimumab Therapy

By

While the MUSICA trial did not establish noninferiority for a lower dosage of MTX when combined with adalimumab, it may be an appropriate option for patients who require a reduction due to MTX toxicity.

Sign Up for Free e-Newsletters